Loading clinical trials...

COMPLETED

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

NCT04676555•Novartis Pharmaceuticals

Summary

This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia.

Detailed Description

Patients with RMS receiving Ocrelizumab or Ofatumumab will be recruited to measure the time spend for Healthcare Providers (HCP) (neurologist, nurse and hospital pharmacist) on preparing, administering the medication and following up with the patient.

Eligibility

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients of 18 or more years of age.
•Patients with confirmed diagnosis of RMS (CIS, RRMS or aSPMS) following 2017 McDonnald criteria.
•Patients currently prescribed with Ocrelizumab or Ofatumumab to treat MS according to the Summary of Product Characteristics (SmPC). The decision must be based on patient disease and taken before the decision of inviting the patient to participate in this study.
•Patients literate in English.
•Patients must provide informed consent to participate in the study.

Exclusion Criteria

•Patients currently participating in any other RMS clinical trial.

Locations (2)

Novartis Investigative Site

Lutherville, Maryland, United States

Novartis Investigative Site

Parkville, Victoria, Australia

Key Dates

Start Date

May 11, 2021

Primary Completion Date

October 21, 2021

Completion Date

October 21, 2021

Last Updated

October 24, 2022

Enrollment

ACTUAL participants

Conditions

Relapsing Forms of Multiple Sclerosis

Interventions

Ocrelizumab

DRUG

Ofatumumab

DRUG

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

NCT06681623

Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

View study

COMPLETED

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice

NCT06251986

Relapsing Forms of Multiple Sclerosis

View study

COMPLETEDPHASE3

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 24, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.